Product Description
selective androgen receptor modulator (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20356837/)
Mechanisms of Action: SARM Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sarcopenia
Phase 1: Healthy Volunteers|Osteoporosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01017458 |
MK-0773-004 | P1 |
Completed |
Healthy Volunteers |
2008-08-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01011725 |
MK0773-003 | P1 |
Completed |
Osteoporosis |
2006-04-01 |
2022-05-04 |
Primary Endpoints |
|
NCT00529659 |
MK-0773-005 | P2 |
Completed |
Sarcopenia |
2009-10-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2007-002383-95 |
Sarcopenia Study | P2 |
Completed |
Sarcopenia |
2009-10-01 |
2022-03-12 |
Treatments |